Cancer Cases of Zhi Chen Guo

Peter Hudoba MD, FRCS
NYIT, New York
March 29, 2007
Guo’s Study
Follow up in Person
Subgroup with No conventional Th
15/32 Patients

Follow up in person:

• 2 died (unknown when, likely 1999-2004)
• 2 unknown
• 6 seen in centre 2007 (still working)
• 5 seen in centre 2005 (? State, able to come to clinic)
• Estimated 73% patients has Karnofsky 100%
• Survival AVG 8.8 years, (2 new cases 1 y, rest 5-15 y)
• 5 y survival 100%, 7 y survival 81.1% (11 cases)
Guo’s Study
Survival - Diagnosis
Subgroup with No conventional Th
15/32 Patients

Survival - Diagnoses:

• Lung Cancer: 15y, 9y - still alive; one diagnosed 1 y ago - still alive, one 5y and likely dead
• Liver Cancer: 7y, 10y - still alive; 1 5y died
• Esophageal Cancer: 14 -still alive; 1 ? 1-5y - died
• Pancreas: 10y, 11y - still alive
• Endometrium: 9 y - still alive
• Galbladder: at least 1 y, unknown if died
• Mucosarcoma: diagnosed 1 y ago, still alive
• Ovary cancer: 14 y - still alive
Guo’s Study

Follow up Test Results

Subgroup with No conventional Th

15/32 Patients

- Time of FU after Initial Diagnosis Avg 27.4 m (1-110 m)
- 5 CT: Normal
- 5 US: Normal
- 1 XRAY: Normal
- 1 Endoscopic exam: Normal
- 3 Follow up results not available
Conclusion

• Although documentation grossly incomplete, available results suggest positive effect
• Results warrant Stage 2 Clinical Trial in controlled settings